CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Financial highlights
| Metric | FY December 27, 2025 | FY December 28, 2024 | FY December 30, 2023 | FY December 31, 2022 | FY December 25, 2021 |
|---|---|---|---|---|---|
| Revenue | $4.0B | $4.0B | $4.1B | $4.0B | $3.5B |
| Operating income | $25.2M | $227.3M | $617.3M | $651.0M | $589.9M |
| Cash from operations | $737.6M | $734.6M | $683.9M | $619.6M | $760.8M |
| Capital expenditure | $219.2M | $233.0M | $318.5M | $324.7M | $228.8M |
| Free cash flow | $518.5M | $501.6M | $365.4M | $294.9M | $532.0M |
| Share repurchases | $360.7M | $119.2M | $24.2M | $38.7M | $40.7M |
| Impairments | $165.0M | $215.0M | $0 | $0 | $0 |
| Total assets | $7.1B | $7.5B | $8.2B | $7.6B | $7.0B |
| Total liabilities | $3.9B | $4.0B | $4.5B | $4.6B | $4.4B |
| Total debt | $2.1B | $2.2B | $2.6B | $2.7B | $2.7B |
Shares outstanding 48.2M · Free float 98.6%
Annual filing data through FY ended December 27, 2025; float as of July 12, 2026.